This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The Immunophenotyping Core is a new addition to our COBRE portfolio and is based upon the requests and evolving research needs of our COBRE Junior Investigators, Pilot Project applications and other COBRE eligible investigators. This Core will assist investigators in assessing cellular biomarkers and responses in specific human blood cell subpopulations using multiparameter, high content cellular assays. With the rapidly growing complex human disease genome wide association data, our researchers are requiring new resources that enable them to ask relevant questions about biological functions of associated genes and pathways in human samples. The ability to test biological responses in fresh human cells while gathering the maximum information from these valuable samples is extremely important, as it allows evaluation of pathogenic mechanisms, development of new biomarkers of disease activity or prognostic outcomes, and exploration of the initial events in systemic autoimmunity and response to human vaccination. The Clinical Core houses thousands of viable frozen peripheral blood cells from patients and controls. COBRE investigators can use these and freshly isolated samples from the same individuals for detailed immunophenotyping and biological response testing to enhance the ability of COBRE investigators in performing cutting-edge research. The Immunophenotyping Core expands upon traditional signal transduction and flow cytometric methods, embracing current state-of-the-art technologies for assessing multiple signal transduction parameters and cellular biomarkers in multiple cell types using multiparameter flow cytometry and high-content/high- throughput cellular bioassays. The Core provides COBRE investigators with technology, reagents and expertise to enable efficient adoption of these approaches in their research. The three aims of the Core which are designed to meet the needs of our investigators are to (1) provide access to technical expertise in the development of customized multiparameter flow cytometry biomarker and signaling assays on fresh whole blood and/or frozen peripheral blood mononuclear cells, (2) supply cost- effective access to current state-of-the-art technologies and methods for analysis of cell responses in high-throughput/high- content in vitro cellular bioassays, and (3) assess and acquire new technologies and develop new methods for the analysis of multiparameter flow cytometric, high-content image-based and signaling/response-based cellular assays that can further enhance the capabilities of COBRE researchers to do cutting-edge research at the clinical-translational interface.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-RI-2 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oklahoma Medical Research Foundation
Oklahoma City
United States
Zip Code
Waubant, Emmanuelle; Mowry, Ellen M; Krupp, Lauren et al. (2013) Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler 19:891-5
Koelsch, Kristi A; Webb, Ryan; Jeffries, Matlock et al. (2013) Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J Autoimmun 41:168-74
Smith, Kenneth; Muther, Jennifer J; Duke, Angie L et al. (2013) Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. Immunobiology 218:745-54
Cogman, Abigail R; Chakravarty, Eliza F (2013) The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine 31:3640-3
Ramos, Paula S; Oates, James C; Kamen, Diane L et al. (2013) Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol 40:842-9
Weckerle, Corinna E; Mangale, Dorothy; Franek, Beverly S et al. (2012) Large-scale analysis of tumor necrosis factor ? levels in systemic lupus erythematosus. Arthritis Rheum 64:2947-52
Adrianto, Indra; Wang, Shaofeng; Wiley, Graham B et al. (2012) Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum 64:3695-705
James, Judith A; Robertson, Julie M (2012) Lupus and Epstein-Barr. Curr Opin Rheumatol 24:383-8
Wang, S; Adrianto, I; Wiley, G B et al. (2012) A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun 13:380-7
Niewold, Timothy B; Kelly, Jennifer A; Kariuki, Silvia N et al. (2012) IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 71:463-8

Showing the most recent 10 out of 46 publications